These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 3265377

  • 21. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.
    Schmalreck AF, Wildfeuer A.
    Arzneimittelforschung; 1990 Oct; 40(10):1145-55. PubMed ID: 2291754
    [Abstract] [Full Text] [Related]

  • 22. [Errors of the agar diffusion method to predict Escherichia coli's susceptibility to ampicillin-sulbactam and amoxicillin-clavulanic acid].
    Villar HE, Jugo MB, Fernández-Lausi A, Farinati AE.
    Enferm Infecc Microbiol Clin; 1996 May; 14(5):308-10. PubMed ID: 8744371
    [Abstract] [Full Text] [Related]

  • 23. Beta-lactamase inhibitors from laboratory to clinic.
    Bush K.
    Clin Microbiol Rev; 1988 Jan; 1(1):109-23. PubMed ID: 3060240
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Comparison of four beta-lactamase inhibitors in combination with ampicillin against Mycobacterium tuberculosis.
    Sorg TB, Cynamon MH.
    J Antimicrob Chemother; 1987 Jan; 19(1):59-64. PubMed ID: 3030999
    [Abstract] [Full Text] [Related]

  • 27. Use of beta-lactam/beta-lactamase-inhibitor combinations as antimycobacterial agents.
    Prabhakaran K, Harris EB, Randhawa B, Adams LB, Williams DL, Hastings RC.
    Microbios; 1993 Jan; 76(309):251-61. PubMed ID: 8302203
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Bactericidal action of ampicillin/sulbactam against intracellular mycobacteria.
    Prabhakaran K, Harris EB, Randhawa B.
    Int J Antimicrob Agents; 1999 Oct; 13(2):133-5. PubMed ID: 10595573
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Activity of beta-lactamase inhibitor sulbactam plus ampicillin against animal isolates of Pasteurella, Haemophilus, and Staphylococcus.
    Girard AE, Schelkly WU, Murphy KT, Sawyer PS.
    Am J Vet Res; 1987 Dec; 48(12):1678-83. PubMed ID: 3501686
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Development of beta-lactamase inhibitors.
    Sutherland R.
    J Reprod Med; 1990 Mar; 35(3 Suppl):307-12. PubMed ID: 2319512
    [Abstract] [Full Text] [Related]

  • 39. [A comparison of the in vitro susceptibility of three bacteria to beta-lactamase inhibitors and to ampicillin and cefazolin].
    Acar N, Diri MC, Türkyilmaz FR.
    Mikrobiyol Bul; 1987 Oct; 21(4):284-8. PubMed ID: 3332705
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.